PofoliaShared via Pofolia

New England Journal of Medicine· 2025Q1

A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus

M. Luciano, Michael A. Williams, Mark G. Hamilton, Heather Katzen et al.

Short summary

In patients with idiopathic normal-pressure hydrocephalus selected by CSF drainage response, shunting improved gait velocity by 0.21 m/s and Tinetti scale scores by 2.4 points at 3 months compared to placebo.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Shunting improved gait velocity by 0.21 m/s (P<0.001) and Tinetti scale scores by 2.4 points (P=0.003) at 3 months compared to placebo.
  • No significant improvements were observed in Montreal Cognitive Assessment (MoCA) or Overactive Bladder Questionnaire scores.
  • Participants selected for shunting had shown improvement in gait velocity with temporary CSF drainage.
  • Adverse events included more falls in the placebo group, but more subdural bleeding and positional headaches in the open-shunt group.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, but the effectiveness of shunting is unclear. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving participants selected for shunt surgery on the basis of gait-velocity improvement with cerebrospinal fluid (CSF) drainage. Participants were randomly assigned to an open-shunt valve setting (opening pressure, 110 mm of water) or a placebo valve setting (opening pressure, >400 mm of water) of a noninvasively adjustable shunt. The primary outcome was the change in gait velocity 3 months after surgery. Secondary outcomes were the change at 3 months in the Tinetti scale total score (range, 0 to 28; lower scores indicate worse gait and balance), Montreal Cognitive Assessment (MoCA) score (range, 0 to 30; lower scores indicate worse cognition), and Overactive Bladder Questionnaire score (range, 0 to 100; higher scores indicate worse urinary incontinence). RESULTS: A total of 99 participants underwent randomization and received the assigned intervention. At 3 months, gait velocity had increased in the open-shunt group (mean [±SD] change, 0.23±0.23 m per second; assessed in 49 participants) and was unchanged in the placebo group (mean change, 0.03±0.23 m per second; assessed in 49 participants), resulting in a treatment difference of 0.21 m per second (95% confidence interval, 0.12 to 0.31; P<0.001). A significantly greater improvement in the open-shunt group than the placebo group was seen for the Tinetti scale score (mean change, 2.9 points vs. 0.5 points; P = 0.003) but not the MoCA score (1.3 points vs. 0.3 points) or the Overactive Bladder Questionnaire score (-3.3 points vs. -1.5 points). The results regarding adverse events were mixed, with more participants in the placebo group reporting falls (46% vs. 24%), an equal percentage having cerebral bleeding (2% in both groups), and more participants in the open-shunt group having subdural bleeding (12% vs. 2%) and positional headaches (59% vs. 28%). CONCLUSIONS: Among participants with idiopathic normal-pressure hydrocephalus who had a response to temporary CSF drainage, shunting resulted in significant improvements at 3 months in gait velocity and a measure of gait and balance but not in measures of cognition or incontinence. (Funded by the National Institute of Neurological Disorders and Stroke and the Trial Innovation Network; PENS ClinicalTrials.gov number, NCT05081128.).

The authors' abstract, as published at the source. New England Journal of Medicine, 2025 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Cellular and Molecular Neuroscience

Cellular and Molecular NeuroscienceNeuroscience